Evidence map›Paper›PMID 24465606›Full record

ArticlePloS one2014

Comparison of antiviral activity between IgA and IgG specific to influenza virus hemagglutinin: increased potential of IgA for heterosubtypic immunity.

Mieko Muramatsu, Reiko Yoshida, Ayaka Yokoyama, Hiroko Miyamoto, Masahiro Kajihara, Junki Maruyama, Naganori Nao, Rashid Manzoor, Ayato Takada

Open access · goldAbstract readComparative Study
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers.

0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

67 citing papers in PubMed, 92 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Neutralization of the Pandemic Influenza A/H1N1 Virus withAntibodies (Basel, Switzerland) · 2025
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

7 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 2 countries.

Mieko MuramatsuDivision of Global Epidemiology, Research Center for Zoonosis Control, Hokkaido University, Sapporo, Japan.
Reiko YoshidaDivision of Global Epidemiology, Research Center for Zoonosis Control, Hokkaido University, Sapporo, Japan.
Ayaka YokoyamaDivision of Global Epidemiology, Research Center for Zoonosis Control, Hokkaido University, Sapporo, Japan.
Hiroko MiyamotoDivision of Global Epidemiology, Research Center for Zoonosis Control, Hokkaido University, Sapporo, Japan.
Masahiro KajiharaDivision of Global Epidemiology, Research Center for Zoonosis Control, Hokkaido University, Sapporo, Japan.
Junki MaruyamaDivision of Global Epidemiology, Research Center for Zoonosis Control, Hokkaido University, Sapporo, Japan.
Naganori NaoDivision of Global Epidemiology, Research Center for Zoonosis Control, Hokkaido University, Sapporo, Japan.
Rashid ManzoorDivision of Global Epidemiology, Research Center for Zoonosis Control, Hokkaido University, Sapporo, Japan.
Ayato TakadaDivision of Global Epidemiology, Research Center for Zoonosis Control, Hokkaido University, Sapporo, Japan ; School of Veterinary Medicine, the University of Zambia, Lusaka, Zambia.
Hokkaido University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Both IgA and IgG antibodies are known to play important roles in protection against influenza virus infection. While IgG is the major isotype induced systemically, IgA is predominant in mucosal tissues, including the upper respiratory tract. Although IgA antibodies are believed to have unique advantages in mucosal immunity, information on direct comparisons of the in vitro antiviral activities of IgA and IgG antibodies recognizing the same epitope is limited. In this study, we demonstrate differences in antiviral activities between these isotypes using monoclonal IgA and IgG antibodies obtained from hybridomas of the same origin. Polymeric IgA-producing hybridoma cells were successfully subcloned from those originally producing monoclonal antibody S139/1, a hemaggulutinin (HA)-specific IgG that was generated against an influenza A virus strain of the H3 subtype but had cross-neutralizing activities against the H1, H2, H13, and H16 subtypes. These monoclonal S139/1 IgA and IgG antibodies were assumed to recognize the same epitope and thus used to compare their antiviral activities. We found that both S139/1 IgA and IgG antibodies strongly bound to the homologous H3 virus in an enzyme-linked immunosorbent assay, and there were no significant differences in their hemagglutination-inhibiting and neutralizing activities against the H3 virus. In contrast, S139/1 IgA showed remarkably higher cross-binding to and antiviral activities against H1, H2, and H13 viruses than S139/1 IgG. It was also noted that S139/1 IgA, but not IgG, drastically suppressed the extracellular release of the viruses from infected cells. Electron microscopy revealed that S139/1 IgA deposited newly produced viral particles on the cell surface, most likely by tethering the particles. These results suggest that anti-HA IgA has greater potential to prevent influenza A virus infection than IgG antibodies, likely due to increased avidity conferred by its multivalency, and that this advantage may be particularly important for heterosubtypic immunity.

Indexed as

AnimalsAntibodies, ViralAntiviral AgentsDogsElectrophoresis, Polyacrylamide GelHemagglutination Inhibition TestsHemagglutinin Glycoproteins, Influenza VirusHumansImmunityImmunoglobulin AImmunoglobulin GInfluenza, HumanMadin Darby Canine Kidney CellsMiceNeutralization TestsOrthomyxoviridae InfectionsAntibodies, ViralAntiviral AgentsHemagglutinin Glycoproteins, Influenza VirusImmunoglobulin AImmunoglobulin G

Identifiers

PMID24465606
PMCPMC3895000
OpenAlexW2016244758

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.